Natural history of irritable bowel syndrome by El-Serag, Hashem B. et al.
Systematic review: natural history of irritable bowel syndrome
H. B. EL-SERAG*, , P. PILGRIM & P. SCHOENFELD
*Division of Gastroenterology, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA;
Division of Health Services Research, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA;
Division of Gastroenterology, University of Michigan School of Medicine and Center for Excellence in Health
Services Research, Veterans Affairs Medical Center, Ann Arbor, MI, USA
Accepted for publication 13 February 2004
SUMMARY
Background: The natural history of irritable bowel
syndrome is unclear, including the likelihood that
these patients will be diagnosed with an alternative
organic or functional3 gastrointestinal disorder. Under-
standing the stability of an irritable bowel syndrome
diagnosis may limit repeated diagnostic evaluation
among these patients.
Methods: The inclusion criteria included observational
longitudinal studies of clinic-based samples of adult
patients with irritable bowel syndrome. Only studies
published in the English language in full manuscript
form were included. Literature searches, selection and
review of eligible articles, and data abstraction were
performed in a duplicate, independent manner.
Results: Fourteen studies met study selection criteria. In
six studies with relevant information, 2–5% of irritable
bowel syndrome patients were diagnosed with an
alternative organic GI disorder after 6 months to
6 years of follow-up. Long-term follow-up indicated
that 2–18% of patients developed worse irritable bowel
syndrome symptoms, approximately 30–50% of
patients had unchanged symptoms, and the rest either
improved or had symptoms disappear. Prior surgery
(one study), higher somatic scores (one study), higher
baseline anxiety (two studies), depression scores (one
study) were predictive of worsening of symptoms during
long-term follow-up.
Conclusions: Irritable bowel syndrome, a chronic disor-
der, is a stable diagnosis. Once initial investigations are
negative, fewer than 5% are diagnosed with an
alternative organic GI disorder. Repeated diagnostic
evaluations of patients with recurrent or persistent
symptoms similar to their baseline symptoms are not
warranted.
INTRODUCTION
Irritable bowel5 syndrome (IBS) is a chronic relapsing
condition that is diagnosed with symptom-based cri-
teria.1 Most patients with IBS undergo exhaustive
diagnostic evaluations to rule out other organic GI
disorders before physicians and/or patients accept this
diagnosis.2 The natural history of IBS has been
described as a chronic course with intermittent flares.1
Thus, this natural history lends itself to repeated
diagnostic evaluations at considerable expense while
exposing the patient to procedure-related complications.
The natural history of IBS, including the stability of a
symptom-based IBS diagnosis and the frequency and
duration of symptomatic IBS flares, is poorly documen-
ted. Previous studies3, 4 estimate the likelihood of
diagnosing an alternative organic GI disorder during
prolonged follow-up of IBS patients. Previous studies5
also suggest that some patients with IBS transition into
other functional GI disorders. In order to minimize
repeated expensive and potentially morbid diagnos-
tic evaluations in these patients, it is important to
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determine the stability of an IBS diagnosis and the
frequency that IBS transitions to alternative functional
GI disorders. Therefore, knowledge of the natural history
of IBS is relevant to primary care providers, gastroen-
terologists and health care policy makers. Although a
previous systematic review6 discussed the clinical course
and prognostic determinants of IBS, it did not provide a
detailed account of the stability of an IBS diagnosis, the
frequency of transition to alternative functional GI
disorders, or the frequency and duration of symptomatic
IBS flares. The current report provides an updated
systematic review with new publications and with a
detailed evaluation of the natural history of IBS.
Therefore, this systematic review of published litera-
ture encompasses the following objectives: (i) to deter-
mine the stability of the IBS diagnosis (i.e. to determine
the likelihood that an alternative organic GI disorder
would be diagnosed after an initial diagnosis of IBS); (ii)
to determine the likelihood that IBS patients would
transition to alternative functional GI disorders; (iii) to
characterize the frequency and duration of symptomatic
flares of IBS; (iv) to identify limitations in the current
research; and (v) to identify areas for future research.
MATERIALS AND METHODS
Literature search
A computer-assisted search using the OVID interface to
MEDLINE and EMBASE was conducted to identify
potentially relevant published papers. A search of the
MEDLINE database from 1966 to present was performed
using the exploded (exp) medical subject heading
(MeSH) terms (exp irritable bowel syndrome) AND
(exp incidence OR exp prevalence OR exp epidemiology
OR exp natural history OR exp clinical course OR exp
prognosis). An identical search of the biomedical and
pharmaceutical EMBASE database from 1990 to 2003
was also performed. The results in all searches were
limited to human studies published in the English
language. Manual searches of reference lists from
potentially relevant papers were also performed to
identify any additional studies that may have been
missed using the computer-assisted strategy.
Study selection criteria
Two investigators (H.E., P.P.) independently reviewed
the titles and abstracts of all citations identified by the
literature search. Potentially relevant studies were
retrieved and the selection criteria applied. The inclu-
sion criteria were (i) longitudinal studies of clinic-based
samples of adult patients; (ii) IBS had to be defined
according to either conventional definitions or some
operational definition documented by the investigators;
(iii) total number of the inception cohort had to be
available; (iv) total number of subjects available at the
end of follow-up was reported; (v) the study was
observational; and (vi) published in the English
language in full manuscript form. The exclusion
criteria included: (i) therapy trials; and (ii) cross
sectional studies with no follow-up. Population-based
studies were not included because patients in these
studies did not uniformly have a physician-based
diagnosis of IBS.
Data extraction and data analysis
The eligible articles were reviewed in a duplicate,
independent manner by two investigators (H.E., P.P.).
Agreement on selection of studies was 100%. Data
abstraction on predesigned forms was also performed
in a duplicate, independent fashion by the two
investigators. Agreement between investigators was
>90% and disagreement in data extraction was
resolved by consensus. For studies regarding the
stability of the IBS diagnosis, the incidence of alternat-
ive organic GI disorder diagnoses, timing of diagnosis,
and type of alternative organic GI disorder was
extracted. For studies about the progression of IBS
diagnosis to another functional GI disorder, the
incidence of alternative functional GI disorders, the
timing of diagnosis of alternative functional GI disor-
der, and type of alternative functional GI disorder was
extracted. For studies about the frequency of flares of
IBS, the frequency of IBS flares and the duration of IBS
flares were extracted. If data were available, we
calculated the proportions of patients with IBS who
developed alternate organic disease, or functional
disorder during follow-up, and the proportion of
patients with IBS who become asymptomatic at the
end of follow-up. Drop out rates were presented or
calculated from the available data. We also specifically
abstracted the study design (retrospective/prospective),
duration of follow-up, demographic features of the
study population and determinants of outcomes
(if any). The data was presented in a tabular and
graphic format.
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RESULTS
Characteristics of selected studies
Searching the MEDLINE database yielded 539
articles in the in the titles search; the EMBASE
database yielded 372 articles. There were several
articles found in more than one search, and a net total
of 22 articles were found. The titles and abstracts of
these 22 articles were reviewed by two authors (H.E.,
P.P.).
The literature search identified 14 relevant studies
that met our initial criteria3, 4, 7–18. (Table 1) These
included 10 studies identified in the previously pub-
lished review6 in addition to three studies excluded by
that review,11, 12, 17 and one recent study.14 One
additional study19 was not abstracted because it
examined the same cohort of an earlier study.4 All
studies were clinic-based: seven prospective7, 10, 12, 15–18
and seven retrospective.3, 4, 8, 9, 11, 13, 14 Chaudhary
et al.8 published the earliest study in 1962 and Keefer
et al.14 published the most recent article in 2002. The
studies were conducted in four countries. Most studies
(n ¼ 8) were conducted in the UK,7–11, 13, 16, 18 and
four studies were conducted in the United
States.3, 7, 14, 15, 17
The prospective studies were generally smaller in
sample size (n ¼ 20–104) as compared with retrospec-
tive studies (n ¼ 75–163). Also, the follow-up was less
complete in prospective (47–100%) than in retrospec-
tive studies (four of seven had >80% follow-
up).3, 4, 8, 11, 13 Women comprised the majority of study
subjects (36–100%) in most studies. Most studies
employed some definition for IBS that combined abdom-
inal pain with altered bowel move-
ments,3, 7, 9, 10, 12, 13, 16, 18 although three studies
might have included patients without abdominal
pain.8, 11, 18 Only five studies categorized patients with
IBS as diarrhoea-dominant, constipation-dominant or
alternating; these particular studies were published after
1983.3, 4, 10, 12, 17 Many of the studies listed sigmoidso-
copy (n ¼ 7) and barium enema (n ¼ 5) as part of the
IBS definition.4, 7, 8, 11–13, 18 Ten studies recorded the
duration of IBS symptoms prior to the onset of follow-
up. Generally, these studies included patients with
chronic IBS symptoms (few weeks to 20 years) with
four studies having patients with >10 years of IBS
symptoms. The primary outcome of most studies was
the persistence or resolution of the presumed IBS
symptoms.
Likelihood of diagnosing an alternative organic GI disorder
after an initial IBS diagnosis
The development of alternative or consequent organic
diseases was specifically addressed in six of 14 studies
(Table 2).3, 4, 11, 13, 16, 18 The proportion of patients
developing organic diseases after baseline investigation
ranged between 2 and 9% of those who completed
follow-up and 1.4–9% of the original cohort when
followed for up to 30 years. When follow-up is limited to
6 months to 6 years after original IBS diagnosis, only
2–5% of IBS patients were diagnosed with an alternat-
ive organic GI disorder during follow-up. In the studies
that reported organic disease development, five of six
reported baseline investigations4, 11, 13, 18 that consis-
ted of sigmoidoscopy (four studies), barium enema (five
studies), and/or blood work including haemoglobin,
ESR (three studies). In these studies, the proportions of
patients developing alternative organic disease also
ranged between 2 and 5%.
In the first of these studies,18 only one patient (2%)
developed a gastric ulcer, and none of the patients
reported weight loss or hospitalization during an
average follow-up of 12 months. In the second and
largest of these four studies,11 six (3.7%) of 163 patients
had a new gastrointestinal diagnosis during the follow-
up: adenocarcinoma of the stomach (two patients)
<1 and 4 years after initial consultations; adenocarci-
noma of the colon (two patients) found 2 and 6 years
respectively, after initial investigation; ulcerative colitis
(one patient) developed 5 years after the onset of
symptoms and 3 years after normal sigmoidsocopy;
and pancreatic steatorrhoea developed in the final
patient who declined further investigations. In the third
study,13 four patients (5%) developed alternative
organic diagnoses over a follow-up of 6 years: one
patient was diagnosed with gastric ulcers, one was
discovered to have jejunal diverticulum with possible
bacterial overgrowth, and the remaining two patients
had thyroid dysfunction. The fourth study,4 reported
that five patients (4.5%) were considered diagnostic
failures: one patient died of bronchogenic carcinoma
6 months after IBS diagnosis and autopsy revealed
chronic pancreatitis; another died of pancreatic cancer
18 months after IBS diagnosis. The remaining three
patients had symptomatic gallbladder stones, kidney
stones, or thyrotoxicosis during follow-up.
Lastly, the study by Owen et al.3 was the one that
reported the highest proportion of organic diagnoses
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(10 patients or 9%). However in that study, only one
patient (0.9%) developed gastric ulcer that was detected
after a relatively short time (2 years) and therefore was
felt to be related to the initial diagnosis of IBS. Eight of
the nine remaining patients developed alternative
organic GI disorders more than 12 years after the
original IBS diagnosis: chronic pancreatitis (n ¼ 2; 17
and 30 years later), gastrointestinal cancer (n ¼ 4;
13–30 years later), small bowel obstruction (n ¼ 2; 2
and 12 years later), and gastric ulcer (n ¼ 1;12 years
later). Thus, it is unlikely that the original IBS diagnosis
was a mis-diagnosis of an underlying organic GI
disorder.
Given the relatively small number of patients devel-
oping organic disease in each study, proper examina-
tion of risk factors for developing alternative organic
disease could not be performed.
Likelihood that IBS patients transition to an alternative
functional GI disorder
No study meeting our inclusion criteria directly
addressed the development of other functional gut
disorders (e.g. chronic constipation, functional dyspep-
sia). One study observed that most patients who
retained symptoms had the same nature of symptoms
(Table 2).18 In that prospective study conducted in the
UK and published in 1969, an analysis performed at the
end of 12-month follow-up revealed that of patients
who retained symptoms (88% of the initial 50 patients),
all but one had a constant nature of symptoms. In the
same study, an analysis was also conducted at the end
of 31-month follow-up that showed 81% of available
symptomatic patients retained the same nature of
symptoms. This single study did not address develop-
ment of other functional GI disorders.
Frequency and duration of symptomatic flares of IBS
All studies reported on symptoms of IBS at the end of
follow-up (Table 2). The reported proportion of patients
with the complete disappearance of symptoms ranged
between 12 and 38% in the five studies that reported on
symptom-free patients.8, 10, 13, 16–18 The median fol-
low-up duration in these studies was 2 years. A sixth
study3 reported that 29% of patients did have IBS-
related visits during a median follow-up of 12 years. In
general, there was no significant correlation between
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symptoms and the duration of follow-up or the duration
of IBS symptoms. Four studies4, 9, 12, 18 reported on the
proportion of patients with unchanged symptoms
(30–50%) and patients whose symptoms had worsened
(2–18%). None of the studies had details about the
frequency and duration of IBS flares.
Only seven studies examined the determinants of
recurrence or persistence of symptoms.3, 4, 7, 9, 12, 14, 17
These are listed in detail in Table 2. Prior surgery (one
study), higher somatic scores (one study), higher
baseline anxiety (two studies), depression scores (one
study) were predictive of worse outcomes in those
studies. While one study reported constipation-predom-
inant IBS,9 another found painless diarrhoea14 as a
favourable prognostic indicator. One study reported
short duration (<2 years) of IBS symptoms to be a
predictor of better prognosis.15 Multivariate analyses
were not conducted in any of the studies.
DISCUSSION
This systematic review indicates that the diagnosis of
IBS is relatively stable after an initial baseline evalua-
tion. In studies that reported a baseline workup, only
2–5% of patients developed alternative organic diagno-
sis during follow-up. In several studies, approximately a
third of all patients diagnosed initially with IBS reported
complete disappearance of their symptoms during a
median follow-up period of 2 years. However, there was
no information on the number and duration of IBS
flares. Finally, the reviewed studies did not provide an
answer to the transition of IBS into other functional gut
disorders such as chronic constipation and functional
dyspepsia.
A previous systematic review by Janssen et al. focused
mainly on the natural history of IBS symptoms, but that
review did not specifically address the main question
examined in our review: the likelihood of diagnosing an
alternative organic GI disorder during follow-up. Fur-
thermore, our updated review includes multiple studies
that were not included in Janssen’s review.10, 11, 13, 16
Also, we did not include population-based stud-
ies,5, 20, 21 which were part of the Janssen review.
These studies identified patients with IBS using symp-
tom questionnaires and further investigations were
usually not conducted. As the primary goal is to
examine the occurrence of organic GI disease in patients
diagnosed with IBS, we have reviewed only clinic-based
studies. These studies provide information on initial
diagnostic work-up, definition of IBS diagnosis, addi-
tional investigation (e.g. sigmoidoscopy, barium enema)
during follow-up, and diagnosis of alternative organic
disorders.
Our major finding is the relatively low likelihood
(2–5%) that patients with well-documented IBS will be
diagnosed with an alternative organic disorder that
accounts for their gastrointestinal symptoms during
long-term follow-up. This is reassuring for patients and
providers and argues against repeated diagnostic work-
ups to look for organic disease. However, most of the
studies in this review pertained to patients referred to
gastroenterology clinics who underwent extensive
investigation including sigmoidoscopy, colonoscopy
and/or barium enema, and stool studies. Patients with
abnormalities in these tests were not included in the
follow-up. Therefore, the stability of the IBS diagnosis
cannot be generalized outside of this setting. In the
future, it would be beneficial to perform long-term
follow-up studies of IBS patients diagnosed in primary
care clinics after a more focused and limited diagnostic
work-up.
Gastric ulcer, gastric cancer and thyroid abnormalities
were the most frequently reported alternative organic
disorders that were identified during follow-up of
patients with IBS. Most of the studies were performed
in the UK during the 1960s and 1970s. The incidence
of gastric (and duodenal) ulcers has been declining
steadily over the past three decades because of the
falling prevalence of Helicobacter pylori infection.22
Therefore, it is unclear if this finding is relevant to
patients seen in the 21st century. Based on this data,
clinicians might consider a thyroid stimulating hor-
mone levels as part of the initial work-up of patients
with IBS. Other organic diagnoses that were reported in
IBS patients included chronic pancreatitis, pancreatic
cancer and gallstones, but these were too infrequent to
warrant specific recommendations. Importantly, we did
not include studies that examined organic diseases in
therapeutic trials, or case reports of possible side effects
of medications.23
The review indicates that IBS symptoms persist in the
majority of patients over a period of several years, but a
substantial minority of IBS patients become symptom-
free within 2 years. Approximately two-thirds of
patients either retain the original symptom severity or
worsen. One study indicated the character of symptoms
remain the same in those who retain these symptoms.12
Unfortunately, our review also identified a relative
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dearth of information on important features of the
clinical course of IBS such as the number, duration, or
risk factors of symptomatic IBS flares. One UK study24
evaluated 122 patients with active IBS flares for
12 weeks. During follow-up, patients reported active
IBS symptoms during 50% of days, reported that they
experienced a mean of 12 distinct ‘episodes’ of active
IBS symptoms during this period and that the maximum
duration of each individual ‘episode’ was 5 days.
Although there is a notion that functional GI disorders
are a continuum with possibly shared pathophysiology
and risk factors, this review indicates a dearth of data to
support this concept. One population-based study,5 a
random sample of 835 residents of Olmsted Co,
Minnesota, who responded to mailed questionnaires
were remailed the same questionnaire 12–20 months
later (83% response rate). The age- and sex-adjusted
prevalence rates for IBS were not significantly different
from the first mailing. Among the 582 subjects free of
IBS on the first survey, 9% developed symptoms, while
38% of the 108 who initially had IBS did not meet the
criteria during follow-up. Similar onset and disappear-
ance rates were observed for the other main symptom
categories (chronic diarrhoea, chronic constipation and
dyspepsia). The substantial turnover with constant
prevalence implied transition between these disorders.
However, in this review in which IBS has a physician-
based diagnosis (unlike the population based study
described above),5 no study was conducted with the
main goal of examining the possible transition between
IBS and other functional bowel disorders. Such infor-
mation is important to clinicians because if we know
that patients with IBS transition to chronic constipation
or functional dyspepsia then this may limit future
diagnostic work-up. This information can also be
important in counselling and reassuring patients with
these symptoms.
This review is limited because we attempted to obtain
information from studies that were not primarily
designed to address our questions. We resorted to a
systematic review with data extraction because of our a
priori knowledge of the paucity of relevant literature. We
also did not include abstracts in this review as we felt
that the details required to answer our questions would
not be provided in most abstracts. We did not employ a
score for methodological quality of the studies because
there is no standard validated scale for this purpose.
Ideal natural history studies of IBS patients might fit
the following criteria: (i) prospective; (ii) all patients
would undergo an appropriate diagnostic evaluation to
rule out alternative organic GI disorders at study entry;
(iii) patients re-evaluated on a regular schedule
(e.g. quarterly or bi-annually); (iv) patients would
complete validated questionnaires about IBS symptom
frequency and duration, quality of life and utilization of
health care resources; and (v) patients would be
followed for prolonged periods (e.g. up to 10 years).
This may be an idealized study that would be difficult to
complete, but it would provide definitive answers about
the natural history of IBS.
In summary, this review indicates that IBS is a stable
diagnosis after an appropriate diagnostic work-up to
rule out alternative organic disorders. Given the chronic
nature of IBS in most patients, repeated testing should
be avoided for patients with recurrent or persistent
symptoms that are similar to their baseline symptoms.
This review also verifies that there is a paucity of data
about the frequency and duration of IBS flares and a
paucity of data about transition of IBS to other
functional GI disorders. Future studies of well-charac-
terized cohorts of IBS patients are needed to address
these questions.
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